Furthermore, the expression levels of Tau, a Cdk5 substrate, have been proposed as a predictive biomarker for paclitaxel response in both breast and gastric cancers, with low Tau expression correlating with better outcomes [166,167]. The gene discussed is MAPT; the disease is gastric cancer.